MedTrace Logo

Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease

NCT00457977 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2015-05-12

Study results available
· View outcomes & findings →

Summary

Pneumococcal disease is a serious bacterial infection that can affect different parts of the body, including the lungs. People with chronic illnesses, such as chronic obstructive pulmonary disease (COPD), have a greater risk of developing pneumonia and meningitis as a result of pneumococcal disease. This study will compare the immune response to two types of pneumococcal vaccines in adults with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

BIOLOGICAL

Pneumovax (PPSV23)

Injection

BIOLOGICAL

Prevnar (PCV7)

Injection

Sponsors & Collaborators

Principal Investigators

  • Antonello Punturieri, MD · National Heart, Lung, and Blood Institute (NHLBI)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00457977 on ClinicalTrials.gov